← All trials
NCT04385043
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2020
- Primary completion
- Oct 15, 2020
- Completion date
- May 15, 2021
- First posted
- May 12, 2020
- Last posted
- May 12, 2020
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Magna Graecia UniversityLead sponsor
- Magna Graecia UniversityReponsible party - principal investigator
- Azienda Ospedaliera Policlinico "Mater Domini"Collaborator
- Annunziata Hospital, Cosenza, ItalyCollaborator
- Azienda Ospedaliera Bianchi-Melacrino-MorelliCollaborator
- Azienda Sanitaria Provinciale Di CatanzaroCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.